Canada / Pharma News Roundup September 2020
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada's consultation with Canadians on what a national strategy for high-cost rare disease…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease drugs could look like. On January 27, 2021, Health Canada launched a consultation on the development of a National Strategy for High-Cost Drugs for Rare Diseases. The consultations (open…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…